Skip to main content
Premium Trial:

Request an Annual Quote

Algonomics Nets $2.7M After Second Closing of VC Round

NEW YORK (GenomeWeb News) — Algonomics has taken in €500,000 ($670,000) in a second closing of a financing round to net a total of €2 million ($2.7 million), the company said today.
 
The immunoprofiling company plans to use the funding to continue developing an in vitro screening platform, called Epibase, to complement its existing screening products and services.
 
Algonomics, based in Ghent, Belgium, said Epibase screens and optimizes biotherapeutics, including therapeutic antibodies, biosimilars, and vaccines.
 
"This investment allows a significant growth of our in vitro assays,” Algonomics CEO Ignace Lasters said in a statement. “Moreover, it allows the further evaluation of novel technologies to address all aspects of immunogenicity.”
 
The company said the second closing was subscribed by Fortis Private Equity and KBC Private Equity, and the funding round was led by Baekeland II fund and subscribed by Gemma Frisius Funds, Flanders Institute for Biotechnology, and TrustCapital.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.